828 completed, 223 recruiting, 200 unknown, 169 terminated. 511 Phase 2, 411 Not applicable, 322 Phase 1, 119 Phase 3, 36 Early Phase 1.
Follow Head and Neck Cancer: new trials by email Literature Review of Head and Neck Cancer trials Research Report on Head and Neck Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Ph2, Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy Colchicine, Placebo - Head and Neck Cancer | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 250 | 2027-03-01 | 2026-10-05 |
| Understanding the Role of MyCareGorithm as a Visual Digital Platforms in Cancer Treatment Education and Patient Comprehension of Oncology Treatment Plans Survey - Head and Neck Cancer, Prostate Cancer | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 94 | 2027-03-01 | 2026-10-01 |
| Maximizing Quality of Life After Cancer Through Rehabilitation TIMELY REHAB - Head and Neck Cancer, Hearing Loss | Not applicable | Not yet recruiting | VA Office of Research and Development | 74 | 2027-03-01 | 2026-06-03 |
| Impact of Chronic MICROplastic Exposure on RADiotherapy of Head and Neck Cancer Patients: Clinical and Translational Oncology Study: Head and Neck Cancer, Microplastic Exposure | Not yet recruiting | University of Kragujevac | 500 | 2027-02-01 | 2026-11-06 | |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Head and Neck Cancer Patients With Oral Mucositis Treated With Ketamine Oral Rinse Placebo, Ketamine Topical - Head and Neck Cancer | Phase 2 | Not yet recruiting | University of Oklahoma | 62 | 2026-12-01 | 2026-10-16 |
| Predictive Factors of Long-term Survivor (LTS) of Patients With Recurrent or Metastatic, Radio-iodine Resistant Differentiated Thyroid Cancer (RRDTC) After Lenvatinib: a Multicenter Study Head and Neck Cancer | Not yet recruiting | IRCCS San Raffaele | 65 | 2026-12-01 | 2026-11-10 | |
| SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET [225Ac]Ac-FL-261 - Solid Tumor, NSCLC | Phase 1 / Phase 2 | Recruiting | Full-Life Technologies UK Limited | 208 | 2026-12-01 | 2026-11-16 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-24 | 2026-11-19 |
| Resistance Training and Creatine Supplementation for Head and Neck Cancer Creatine Supplementation, Resistance Training - Head and Neck Cancer, Cancer Survivorship | Not applicable | Not yet recruiting | Medical University of South Carolina | 30 | 2026-11-15 | 2026-10-06 |
| Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate-Risk Head and Neck Cancer Cisplatin or carboplatin, Intensity-modulated radiation therapy (IMRT) or Intensity-modulated proton therapy (IMPT), Pembrolizumab - Head and Neck Cancer | Phase 2 | Not yet recruiting | Kevin Contrera | 140 | 2026-11-15 | 2026-11-12 |
| Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer RiMO-301, Pembrolizumab, Radiation - Head and Neck Cancer, Head Cancer | Phase 2 | Recruiting | University of Illinois Chicago | 20 | 2026-11-09 | 2026-11-16 |
| Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients Bevonescein (ALM 488) Infusion - Head and Neck Disorder, Head and Neck Cancer | Phase 2 | Recruiting | Matthew Spector | 40 | 2026-11-04 | 2026-11-10 |
| SALI-10 Probiotic to Reduce Osteoradionecrosis and Dental Toxicity Following Radiation Therapy for Head and Neck Cancer Standard of Care (SOC), Experimental drug - Head and Neck Cancer | Phase 3 | Not yet recruiting | University Health Network, Toronto | 288 | 2026-11-01 | 2026-10-20 |
| Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry Proton Transfer Reaction Mass Spectrometry Analysis - Pancreas Cancer, Hepatocellular Carcinoma | Not yet recruiting | University of Oklahoma | 2000 | 2026-11-01 | 2026-11-18 | |
| FLASH Biomarker Study Head and Neck Cancer | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 10 | 2026-11-01 | 2026-11-17 | |
| A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED) Dose de-escalation to contralateral neck., Dose de-escalation to gross disease to contralateral neck, Dose de-escalation to gross disease - Head and Neck Cancer, Head and Neck Squamous Cell Cancer | Phase 2 | Recruiting | University of Maryland, Baltimore | 132 | 2026-10-19 | 2026-11-06 |
| Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC iparomlimab and tuvonralimab combined with cetuximab - Head and Neck Cancer | Phase 2 | Recruiting | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 26 | 2026-10-16 | 2026-10-20 |
| Comparing Radiotherapy Immobilization Systems for Anxious HNC Patients OSMS position management - Head and Neck Cancer, Claustrophobia | Not applicable | Not yet recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 15 | 2026-10-15 | 2026-08-19 |
| Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia Metformin, Naproxen Sodium - Fanconi Anemia, Head and Neck Cancer | Phase 1 | Recruiting | Rockefeller University | 80 | 2026-10-14 | 2026-10-28 |
Showing 20 of 1628. Sign in to see all of them.
Head and Neck Neoplasms (1628) · Squamous Cell Carcinoma of Head and Neck (371) · Lung Neoplasms (172) · Breast Neoplasms (148) · Neoplasms (122) · Carcinoma, Non-Small-Cell Lung (120) · Salivary Gland Neoplasms (100) · Colorectal Neoplasms (95) · Mouth Neoplasms (95) · Ovarian Neoplasms (92) · Pancreatic Neoplasms (92) · Oropharyngeal Neoplasms (91) · Melanoma (86) · Esophageal Neoplasms (85) · Carcinoma, Squamous Cell (82)
Neoplasms by Site (1627) · Neoplasms (1506) · Neoplasms by Histologic Type (629) · Neoplasms, Glandular and Epithelial (558) · Carcinoma (510) · Carcinoma, Squamous Cell (354) · Stomatognathic Diseases (325) · Respiratory Tract Diseases (324) · Respiratory Tract Neoplasms (299) · Digestive System Diseases (280) · Mouth Diseases (271) · Gastrointestinal Diseases (258) · Lung Diseases (249) · Thoracic Neoplasms (246) · Digestive System Neoplasms (234)
Cisplatin (178) · Radiotherapy (145) · Cetuximab (99) · Docetaxel (68) · Fluorouracil (64) · pembrolizumab (62) · Paclitaxel (60) · Carboplatin (58) · Radiotherapy, Intensity-Modulated (51) · Surveys and Questionnaires (38) · Nivolumab (27) · Radiation (27) · Drug Therapy (23) · Erlotinib Hydrochloride (22) · Gemcitabine (21)
M.D. Anderson Cancer Center (57) · Memorial Sloan Kettering Cancer Center (43) · Radiation Therapy Oncology Group (26) · National Cancer Institute (NCI) (24) · Vanderbilt-Ingram Cancer Center (23) · University of Chicago (21) · Dana-Farber Cancer Institute (20) · Wake Forest University Health Sciences (20) · University Health Network, Toronto (19) · Stanford University (17) · Washington University School of Medicine (17) · Case Comprehensive Cancer Center (16) · Eastern Cooperative Oncology Group (16) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (16) · Royal Marsden NHS Foundation Trust (15)
United States (872) · Canada (119) · France (106) · United Kingdom (95) · China (79) · Italy (66) · Belgium (57) · Netherlands (54) · Spain (53) · Germany (50) · Taiwan (47) · South Korea (37) · Australia (30) · Switzerland (23) · Denmark (20)
Barbara Murphy, MD (12) · Quynh-Thu Le (7) · Athanassios Argiris, MD (6) · Corey J. Langer, MD (6) · Jared Weiss, MD (6) · Lillian Siu, MD (6) · Electron Kebebew, MD (5) · Nancy Lee, MD (5) · David G. Pfister, MD (4) · David J. Adelstein, MD (4) · Eben Rosenthal, MD (4) · Everett Vokes, MD (4)
PMID 25057165, PMID 25081901, PMID 31420360, PMID 41343184, PMID 12383306, PMID 15128893, PMID 16467544, PMID 17960012, PMID 30548235, PMID 33340075, PMID 35304084, PMID 37142273, PMID 10071296, PMID 10430262, PMID 10443845, PMID 10444409, PMID 10637264, PMID 10764008, PMID 10772298, PMID 10917373, PMID 10924966, PMID 10961810, PMID 11323096, PMID 11359154, PMID 11560968, PMID 11712783, PMID 11756581, PMID 11822946, PMID 11870186, PMID 12122555, PMID 12361079, PMID 12499279, PMID 12525193, PMID 12525530, PMID 12560776, PMID 12625522, PMID 12676044, PMID 12721240, PMID 12734880, PMID 12788192, PMID 12988177, PMID 14508838, PMID 14529772, PMID 14567906, PMID 14585260, PMID 14616150, PMID 14645636, PMID 14755223, PMID 15033677, PMID 15128894
P30CA068485 (17), P30CA006516 (12), U10CA032102 (11), 2023 (8), 2017 (7), P30CA043703 (7), P30CA012197 (6), P30CA006973 (4), P30CA015083 (4), P30CA016672 (4), P30CA022453 (4), U10CA021115 (4), 2016 (3), P30CA023074 (3), 2005 (2)